Venture
Shoreline Biosciences, Inc.
Latest Form D 2021-11-09- CIK 1818870
- State CA
- Biotechnology
- 3 Form D offerings since 2020-07-22
- Total sold
- $186M
- across 3 offerings
- Rounds
- 3
- Form D offerings since 2020-07-22
- Latest round
- $140M
- 2021-11-09 · 021-420540
- Investors
- 25
- on the latest round
Connected
named in its Form D filingsRound timeline
amount sold · by first filed2021-11-09 · $140M
- 2020-07-22$3M021-371582
- 2021-02-16$43M021-389545
- 2021-11-09$140M021-420540
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($140M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-420540 | First filed2021-11-09 | Latest2021-11-09 | Sought$140M | Sold$140M | Investors25 | Exemptions506(b) |
| 021-389545 | First filed2021-02-16 | Latest2021-02-16 | Sought$43M | Sold$43M | Investors20 | Exemptions506(b) |
| 021-371582 | First filed2020-07-22 | Latest2020-07-22 | Sought$3M | Sold$3M | Investors6 | Exemptions506(b) |
Who backs Shoreline Biosciences, Inc., inferred from co-filings, and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2021-11-09
| Name | Relationship |
|---|---|
| Kleanthis G. Xanthopoulos | RelationshipExecutive Officer, Director |
| Marios Fotiadis | RelationshipDirector |
| Steven Holtzman | RelationshipDirector |
| Dan S. Kaufman | RelationshipDirector |
| Christopher Fuglesang | RelationshipDirector |
| Kimberly Manhard | RelationshipDirector |
| Fan Yu | RelationshipDirector |
| Vanessa Jacoby | RelationshipExecutive Officer |
| William Sandborn | RelationshipExecutive Officer |
| Scott Forrest | RelationshipExecutive Officer |
Sales compensation
Named in Item 12 of its Form D filings
| Recipient | CRD | Broker-dealer | Offerings |
|---|---|---|---|
| Wedbush Securities Inc. | CRD877 | Broker-dealer— | Offerings2 |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- California (CA)
- Exemptions
- Rule 506(b)
- First filed
- 2020-07-22
- Latest filing
- 2021-11-09
Who backs Shoreline Biosciences, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗